Apellis Pharmaceuticals Inc. held its Annual Meeting of Stockholders on June 3, 2025. The stockholders elected A. Sinclair Dunlop, Alec Machiels, and Keli Walbert as class II directors. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, stockholders recommended that future advisory votes on executive compensation be held every year. All proposals were approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-134886), on June 04, 2025, and is solely responsible for the information contained therein.